Imugene Limited
Imugene Limited
Your view on IMU.AX
Overview
What the company does, where it operates, and who runs it.
About Imugene Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Leslie Chong
- Headquarters
- 4-6 Bligh Street, Sydney, NSW, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Leslie Chong
- Headquarters
- 4-6 Bligh Street, Sydney, NSW, AU
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.
Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study.
The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer.
Imugene Limited is headquartered in Sydney, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Imugene Limited. Starting points for Imugene Limited: EPS -AUD 0.30, beta 2.14 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Imugene Limited. Imugene Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Imugene Limited. Trailing twelve-month EPS for Imugene Limited stands at -AUD 0.30. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterJun 2015 | Next quarterJun 2016 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | AUD 0.00 | AUD 0.00 | −AUD 0.06 | −AUD 0.04 |
| Lowest estimate | AUD 0.00 | AUD 0.00 | −AUD 0.08 | −AUD 0.07 |
| Highest estimate | AUD 0.00 | AUD 0.00 | −AUD 0.03 | −AUD 0.03 |
| Number of analysts | 2 | 2 | 2 | 3 |
| A year ago | — | — | −AUD 0.321 | — |
| Growth vs a year ago | — | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterJun 2015 | Next quarterJun 2016 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | AUD 304499.00 | AUD 811999.00 | AUD 1.67M | AUD 16.80M |
| Lowest estimate | AUD 291000.00 | AUD 776000.00 | AUD 1.67M | AUD 16.80M |
| Highest estimate | AUD 306000.00 | AUD 816000.00 | AUD 1.67M | AUD 16.80M |
| Number of analysts | 2 | 2 | 1 | 2 |
| A year ago | — | — | AUD 0.00 | — |
| Growth vs a year ago | — | — | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Imugene Limited. Imugene Limited has reported as a listed company since 1993. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| ACW.AXActinogen Medical Limited | Healthcare | Biotechnology | — | ||
| ALA.AXArovella Therapeutics Limited | Healthcare | Biotechnology | — | ||
| ATH.AXAlterity Therapeutics Limited | Healthcare | Biotechnology | — | ||
| BIO.AXBiome Australia Limited | Healthcare | Medical - Pharmaceuticals | — | ||
| EZZ.AXEZZ Life Science Holdings Limited | Healthcare | Biotechnology | — | ||
| ILA.AXIsland Pharmaceuticals Limited | Healthcare | Biotechnology | — | ||
| PCK.AXPainChek Limited | Healthcare | Medical - Healthcare Information Services | — | ||
| RAD.AXRadiopharm Theranostics Limited | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| ONCO.NEOnco-Innovations Limited | Healthcare | NEO | — | ||
| ONCSQOncoSec Medical Incorporated | Healthcare | OTC | $596 | ||
| ONCYOncolytics Biotech Inc. | Healthcare | NASDAQ | $44.2M | ||
| ONPHOncology Pharma Inc. | Healthcare | OTC | $109,553 | ||
| ONTTFOxford Nanopore Technologies plc | Healthcare | OTC | $1.8B | ||
| OPORFhVIVO plc | Healthcare | OTC | $59.2M | ||
| ORGSOrgenesis Inc. | Healthcare | OTC | $3.0M | ||
| ORICORIC Pharmaceuticals, Inc. | Healthcare | NASDAQ | $795.1M | ||
| ORKAOruka Therapeutics, Inc. | Healthcare | NASDAQ | $6.5B | ||
| ORMPOramed Pharmaceuticals Inc. | Healthcare | NASDAQ | $169.2M | ||
| ORPOFOSE Immunotherapeutics S.A. | Healthcare | OTC | $260.3M | ||
| ORYZFOryzon Genomics S.A. | Healthcare | OTC | $283.9M | ||

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Imugene Limited.